[go: up one dir, main page]

WO2023039373A3 - Crispr-cas effector polypeptides and method of use thereof - Google Patents

Crispr-cas effector polypeptides and method of use thereof Download PDF

Info

Publication number
WO2023039373A3
WO2023039373A3 PCT/US2022/075980 US2022075980W WO2023039373A3 WO 2023039373 A3 WO2023039373 A3 WO 2023039373A3 US 2022075980 W US2022075980 W US 2022075980W WO 2023039373 A3 WO2023039373 A3 WO 2023039373A3
Authority
WO
WIPO (PCT)
Prior art keywords
present disclosure
crispr
cas effector
nucleic acid
disclosure provides
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2022/075980
Other languages
French (fr)
Other versions
WO2023039373A2 (en
Inventor
Basem AL-SHAYEB
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of California Berkeley
University of California San Diego UCSD
Original Assignee
University of California Berkeley
University of California San Diego UCSD
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of California Berkeley, University of California San Diego UCSD filed Critical University of California Berkeley
Publication of WO2023039373A2 publication Critical patent/WO2023039373A2/en
Publication of WO2023039373A3 publication Critical patent/WO2023039373A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • C12N9/22—Ribonucleases [RNase]; Deoxyribonucleases [DNase]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/09—Fusion polypeptide containing a localisation/targetting motif containing a nuclear localisation signal
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/20—Type of nucleic acid involving clustered regularly interspaced short palindromic repeats [CRISPR]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

The present disclosure provides CRISPR-Cas effector polypeptides, nucleic acids encoding same, and compositions comprising same. The present disclosure provides ribonucleoprotein complexes comprising a CRISPR-Cas effector polypeptide of the present disclosure and a guide nucleic acid. The present disclosure provides methods of modifying a target nucleic acid, using a CRISPR-Cas effector polypeptide of the present disclosure and a guide nucleic acid. The present disclosure provides methods of detecting a target nucleic acid, using a CRISPR-Cas effector polypeptide of the present disclosure of the present disclosure and a guide nucleic acid.
PCT/US2022/075980 2021-09-08 2022-09-06 Crispr-cas effector polypeptides and method of use thereof Ceased WO2023039373A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202163241859P 2021-09-08 2021-09-08
US63/241,859 2021-09-08

Publications (2)

Publication Number Publication Date
WO2023039373A2 WO2023039373A2 (en) 2023-03-16
WO2023039373A3 true WO2023039373A3 (en) 2023-08-31

Family

ID=85506855

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2022/075980 Ceased WO2023039373A2 (en) 2021-09-08 2022-09-06 Crispr-cas effector polypeptides and method of use thereof

Country Status (1)

Country Link
WO (1) WO2023039373A2 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12351818B2 (en) 2022-11-23 2025-07-08 Amber Bio Inc. Gene-modifying endonucleases
CN118086463B (en) * 2024-04-17 2024-07-23 湖南工程学院 System and method for detecting Staphylococcus aureus based on nucleic acid aptamers and dendritic CRISPR signal amplification

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20190351074A1 (en) * 2017-02-07 2019-11-21 The Regents Of The University Of California Gene therapy for haploinsufficiency
WO2020181101A1 (en) * 2019-03-07 2020-09-10 The Regents Of The University Of California Crispr-cas effector polypeptides and methods of use thereof
US20210093667A1 (en) * 2017-06-26 2021-04-01 The Broad Institute, Inc. Crispr/cas-adenine deaminase based compositions, systems, and methods for targeted nucleic acid editing

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20190351074A1 (en) * 2017-02-07 2019-11-21 The Regents Of The University Of California Gene therapy for haploinsufficiency
US20210093667A1 (en) * 2017-06-26 2021-04-01 The Broad Institute, Inc. Crispr/cas-adenine deaminase based compositions, systems, and methods for targeted nucleic acid editing
WO2020181101A1 (en) * 2019-03-07 2020-09-10 The Regents Of The University Of California Crispr-cas effector polypeptides and methods of use thereof

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
AL-SHAYEB BASEM, SKOPINTSEV PETR, SOCZEK KATARZYNA M., STAHL ELIZABETH C., LI ZHENG, GROOVER EVAN, SMOCK DYLAN, EGGERS AMY R., PAU: "Diverse virus-encoded CRISPR-Cas systems include streamlined genome editors", CELL, ELSEVIER, AMSTERDAM NL, vol. 185, no. 24, 1 November 2022 (2022-11-01), Amsterdam NL , pages 4574 - 4586.e16, XP093088536, ISSN: 0092-8674, DOI: 10.1016/j.cell.2022.10.020 *

Also Published As

Publication number Publication date
WO2023039373A2 (en) 2023-03-16

Similar Documents

Publication Publication Date Title
MX2022007858A (en) CRISPR-CAS EFFECTOR POLYPEPTIDES AND METHODS OF USE OF THESE.
WO2023039373A3 (en) Crispr-cas effector polypeptides and method of use thereof
WO2023250384A3 (en) Crispr-cas effector polypeptides and methods of use thereof
WO2020102741A8 (en) Methods and compositions for protein sequencing
WO2023102329A3 (en) Effector proteins and uses thereof
EP4524147A3 (en) Anti-vegf protein compositions and methods for producing the same
WO2015130846A3 (en) Compositions and methods for the site-specific modification of polypeptides
WO2020030984A3 (en) Compositions and methods for genome engineering with cas12a proteins
EP4512822A3 (en) C3b binding polypeptide
WO2024119724A9 (en) Collagen peptide, preparation method therefor and use thereof
WO2023034959A3 (en) Polypeptides and methods for modifying nucleic acids
WO2022241059A3 (en) Effector proteins and methods of use
WO2024015875A3 (en) Determination of protein information by recoding amino acid polymers into dna polymers
WO2019229064A3 (en) Method for producing albicanol compounds
WO2011056954A8 (en) Haemophilus parasuis polypeptides and methods of use
WO2024138202A3 (en) Effector proteins, compositions, systems and methods of use thereof
WO2022174099A3 (en) Compositions comprising a variant cas12i4 polypeptide and uses thereof
WO2023147240A3 (en) Variant type v crispr/cas effector polypeptides and methods of use thereof
AU2024229193A1 (en) Engineered proteins and methods of use thereof
AU2024240129A1 (en) Anti-phosphocholine antibodies and methods of use thereof
WO2023220649A3 (en) Effector protein compositions and methods of use thereof
WO2023245005A3 (en) Evolved protein degrons
WO2023064923A3 (en) Fusion effector proteins and uses thereof
WO2019152418A3 (en) Anti-inflammatory compounds and methods of use
WO2023141548A3 (en) Methods for detecting proteins and for co-detecting proteins and nucleic acids, and kits for the same

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 22868241

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 22868241

Country of ref document: EP

Kind code of ref document: A2